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Severe sepsis is a major concern of public health in industrialized countries. It is estimated that in the United States
200,000-400,000 cases occur annually and resulting in an extensive burden for the health care systems. To date, no
FDA-approved pharmacologic agents for the treatment or prevention of human sepsis are available. The current
modalities of therapy in sepsis include the standard arsenal of supportive interventions in critical care medicine and
pharmacotherapy, with use of antibiotics and catecholamines. Despite such efforts, the mortality rates of sepsis have
remained around 30-50 %. Extensive scientific studies have utilized animal models of disease and aimed for a better
understanding of the pathophysiologic mechanisms during sepsis. Members of the IL-17 family of cytokines, as well
as the functionally related IL-23, have been identified as new players in the molecular events during sepsis.
Strategies for targeting these mediators with neutralizing antibodies during experimental sepsis in rodents have
demonstrated efficacy, resulting in improved survival outcomes. Currently, it is not clear whether such findings can
be translated to human sepsis. This review highlights the current knowledge on the biology of IL-17 isoforms and
IL-23 as well as potential applications to clinical medicine.The IL-17 family of cytokines
The first IL-17 family member, IL-17A, was described in
1995 as a cytokine encoded by Herpes virus saimiri [1]. In
humans, IL-17 was first found to be expressed by activated
T cells [2]. Noteworthy, first evidence for the existence of
murine IL-17 originated in 1993 under the name CTLA-8
[3]. IL-17A is a secreted and glycosylated protein with a
molecular mass ~35 kDa. Several other structurally rela-
ted cytokines have since been discovered. This list includes
IL-17B, IL-17 C, IL-17D, IL-17E and IL-17 F. The IL-17E
family member displays only 16 % sequence homology to
IL-17A [4]. This is one of the reasons why IL-17E has also
received the designation IL-25 in the current nomencla-
ture system. On the other hand, a close structural relation
exists for IL-17A and IL-17 F (~50 % homology, depend-
ing on species). A common structural moiety of IL-17
family members includes four conserved cysteine residues.
Formation of disulfide bonds containing these cysteine
residues allows for the assembly of either homodimers or
heterodimers. In terms of biological activity it has been* Correspondence: pward@umich.edu
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reproduction in any medium, provided the origclaimed that IL-17 F is 10-30-fold less potent than IL-17A,
with the IL-17A/F heterodimer having an intermediate
level of activity [5]. The basis for such statements has been
experiments determining the levels of down-stream gene
activation for chemokines such as CXCL-1 after induction
by IL-17A, IL-17 F or IL-17A/F. It should be cautioned
that the results of such studies may not apply to all bio-
logical functions of IL-17 family members or to all clinical
situations in which IL-17 cytokines are expressed. In this
report, the IL-17 family will be referred to as IL-17 s.
Noteworthy, heterodimeric IL-23 has no structural re-
lation to IL-17 family members. IL-23 is composed of
the subunits p19 and p40. Whereas the subunit p40 can
also associate with p35 to form IL-12, no other binding
partner for p19 has been identified so far. Thus, clinical
measurements of IL-23 should preferentially be designed
for specific detection of p19.
Cellular Sources of IL-17 s and IL-23
It is widely agreed that macrophages and dendritic cells
are the major cell sources contributing to the rapid re-
lease of IL-23 during disease. For example, in C57BL/6
mice after a lethal intraperitoneal injection of LPS,
plasma levels of IL-23(p19) peaked as early as 3 hours
[6]. In cell cultures of LPS-activated macrophages, IL-23This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Proposed pathways related to IL-17A and IL-23
production and protective effects related to enhanced innate
immunity or harmful effects due to exaggerated inflammatory
responses.
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rapid induction [6].
For the IL-17 s, the situation is much more complex.
Originally cloned from T cells, it is now clear that IL-
17 s can be produced by a wider variety of immune cells
with phenotypes other than Th17 cells. Release of IL-17
has been demonstrated from neutrophils, lymphocyte-
tissue inducer cells, iNKT cells, γδ T cells and paneth
cells [7,8]. There is also growing evidence that macro-
phages are relevant sources of both IL-17A and IL-17 F
isoforms during the acute inflammatory response [6,9–
11]. The capability of macrophages to induce IL-17 gene
expression may depend on the origin of the macro-
phages, since IL-17A production after LPS was observed
in murine peritoneal elicited macrophages and alveolar
macrophages but not in bone marrow derived macro-
phages after 7 days of maturation in vitro [6].
Biological Functions of IL-17 s and IL-23
There is clear evidence for the role of IL-17 s and IL-27
for the clearance of infectious pathogens. Perhaps more
relevant, their role in the development of autoimmune dis-
eases has been received wide recognition. In experimental
models of rodents developing autoimmune encephalomy-
elitis or collagen-induced arthritis, IL-17 has been linked
to the severity of inflammation in tissues [12,13]. The
differentiation of naïve T cells into the Th17 phenotype
has been shown to be facilitated by the presence of a cyto-
kine milieu containing a combination of TGFβ and IL-6
[14,15]. Subsequently, as a hallmark of Th17 development,
the transcription factor, RORγt, is expressed and activated
[16]. Later stages of Th17 cell differentiation (clonal
expansion, phenotype stabilization with IL-17 production)
also rely on expression of IL-23, which is a potent inducer
of IL-17 [12,13]. It is worth mentioning, that under certain
circumstances IL-17 can also be produced in the absence
of IL-23 and vice versa IL-23 can have biological activities
independently of IL-17 [17]. IL-17 predominantly interacts
with non-leukocytic cells such as epithelial cells, fibro-
blasts and endothelial cells but also macrophages [18].
From these cells, IL-17 initiates production of other proin-
flammatory mediators such as IL-1, TNFα, IL-6, IL-8,
CCL20 and G-CSF, collectively resulting in an influx
of neutrophils. [7,18,19]. IL-17 synergizes with other
mediators such as IL-1, IL-6 and TNFα to activate tissue-
infiltrating neutrophils to facilitate the effective elimin-
ation of invading bacteria or fungi. These concepts are
illustrated in Figure 1.
The IL-17/IL-23 axis and the Complement System
The complement system is an integral part of the innate
immune response against infections by extracellular
pathogens. Since the IL-17/IL-23 axis also directs im-
munologic functions towards the clearance of bacteriaand fungi rather than being involved during viral infec-
tions, the roles of IL-17/IL-23 and the complement sys-
tem would appear to be somewhat redundant. Therefore,
it was no surprise that several interactions between these
two immune defense systems are known to exist. Most
notably, the complement cleavage product, C5a, at
higher doses (25–100 nM) interferes with gene expres-
sion and release of IL-17 family members following LPS-
activation of macrophages. Interestingly, C5a suppressed
production of the potent isoform IL-17A but amplified
the amounts of the weaker isoform IL-17 F [6,9]. Prelim-
inary studies failed to observe consistent effects of C5a
on production of the IL-17A/F heterodimer (Bosmann
and Ward, unpublished findings). At the same time, C5a
very potently antagonizes the release of IL-23(p19) from
LPS-activated macrophages (by more than 80 %) [6]. In
part, the effects of C5a on the IL-17/IL-23 axis can be
attributed by a PI3K/Akt-dependent activation of IL-10
release. This requires ligation of C5a to the C5aR recep-
tor but is independent of the second C5a receptor, C5L2
[6]. While it is clear that C5a drives activation or inhib-
ition of signaling responses in macrophages via PI3K/Akt
pathways, it is unknown why transcription and transla-
tion for IL-10 is enhanced whereas in the case of IL-23,
there is profound suppression of its expression. At least
in macrophages the RORγt transcription factor appears
to be of less relevance for expression of IL-17 s as
opposed to many reports describing the role of RORγt
for Th17 cell differentiation and activation [6,16]. It might
be noted that, in wild type macrophages stimulated with
LPS, there is no measureable expression of mRNA for
RORγt, whereas in IL-10−/− macrophages, addition of LPS
readily upregulates mRNA for RORγt [10]. We speculate
that other yet unidentified intracellular factors must exist
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cluding the IL-17/IL-23 axis. Such factors may act as tran-
scription factors or possibly may have the biochemical
composition of microRNAs.
There are abundant reports on the role of the C5a dur-
ing experimental sepsis in rodents. The blockade or gen-
etic absence of either C5aR or C5L2 improved survival
rates after polymicrobial sepsis (after cecal ligation and
puncture) [20]. Likewise, blockade of C5a by neutralizing
antibodies reduced mortality in such models [21]. Cur-
rently, a phase I clinical trial involving healthy volunteers
and using a humanized monoclonal antibody (IFX-1)
against human C5a during human sepsis has been con-
ducted in Germany. It would be interesting to determine if
blockade of C5a in humans with sepsis affects the levels of
IL-17 isoforms and IL-23 in plasma. Clearly, further stud-
ies in polymicrobial sepsis of rodents are necessary to de-
fine the interactions of the IL-17/IL-23 axis with C5a.
Role of IL-17 s and IL-23 during sepsis
Blockade of IL-17A or IL-23(p19) has been demon-
strated to effectively improve the outcome of endotoxic
shock in C57BL/6 mice (Table 1) [6]. In this study, we
compared anti-IL-17A or anti-IL-23(p19) antibodies to
isotype control antibodies when administered briefly be-
fore intraperitoneal injections with LPS. Treatment with
neutralizing antibody to IL-17A significantly improved
survival rates from 40 % to 100 % and anti-IL-23(p19)
antibody treatment from 10 % to 55 %, respectively. An-
other group has reported on the protective effects of
anti-IL-23(p19) antibodies in a murine model of gram
negative sepsis induced by Pseudomonas aeruginosa [22].
During human sepsis, the mRNA for IL-23(p19) inTable 1 Studies that have investigated the role of IL-17 famil
Reference Species Experimen
[26] M. musculus B. fragilis ch
[23] H. sapiens Expression a
peripheral b
[27] M. musculus E. coli challe
[8] M. musculus CLP
[22] M. musculus P. aeruginos
challenge
[28] M. musculus CLP
[6] M. musculus Endotoxem




CLP Cecal ligation and puncture, DCs Dendritic cells.peripheral blood was elevated above levels found in
healthy individuals [23]. Noteworthy, it has been sug-
gested that dendritic cells from newborns produce higher
levels of IL-23(p19) after LPS activation in vitro when
compared to dendritic cells from adult donors [24]. In
clear contrast, activated monocytes from premature
infants (born before 29 weeks of gestation), who have an
increased risk for neonatal sepsis, showed a defect in
producing the common subunit p40 of IL-12 and IL-23
[25]. If such observations would also apply to p19
remains to be seen.
During polymicrobial sepsis after cecal ligation and
puncture in C57BL/6 J mice the neutralization of IL-17A
by antibody was protective by reducing bacteremia, sys-
temic levels of proinflammatory cytokines/chemokines
and improving survival [8]. γδ T cells were identified as a
cellular source of IL-17A in this study. Using mice genetic-
ally deficient of IL-17A, a different conclusion was reached
in terms of the role of IL-17A for survival of polymicrobial
sepsis [29]. One should be aware that IL-17A deficient
mice can display a compensatory hyperproduction of IL-
17 F in some experimental settings such as LPS-induced
acute lung injury (Bosmann and Ward, unpublished
results). In part, this can be explained by the block in as-
sembly of IL-17A/F heterodimers in the absence of IL-
17A. Another point to consider is the wide variations in
experimental designs of the cecal ligation and puncture
model. There is no standardized consensus on the surgical
protocols employed by different investigators especially in-
cluding issues such as the schemes of fluid resuscitation
and administration of antibiotics.
Interestingly, during both endotoxemia and CLP in mice
the heterodimer IL-17A/F is expressed at 5-10-fold highery members and IL-23 in sepsis
tal Design Main Results






nge Neutralization of IL-17A impaired
peritoneal clearance of E. coli.
Neutralization of IL-17A
reduced mortality.
a Neutralization of IL-23(p19)
reduced mortality.
Production of IL-6, MIP-1α, MIP-2 by
cardiomyocytes required endogenous IL-17A.
ia Neutralization of IL-17A or IL-23(p19)
improved survival. Regulation of IL-17A
and IL-23(p19) by C5a.
ia, CLP C5a dependency of production of IL-17 F.
DCs Defect in the production of IL-12/IL-23
p40 in premature infants.
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mann and Ward, unpublished results). For the future,
investigations using double-knock-out mice (IL-17A−/− IL-
17 F−/−) may provide a clearer picture, since most likely IL-
17A and IL-17 F homodimers have rather redundant roles.
After challenge with live Escherichia coli intraperitone-
ally, a rapid production of IL-17A has been reported and
neutralization of IL-17 resulted in a reduction of neutro-
phil infiltration together with impaired bacterial clear-
ance [27]. Another report has investigated the presence
of IL-17 producing T cells in the wall of abdominal
abscesses following infection with Bacteroides fragilis
[26]. Neutralization of IL-17 prevented abscess forma-
tion. This may suggest a potential role for IL-17 in con-
straining the spread of infection, presumably a critical
event preceding the manifestation of sepsis.
Another hallmark of sepsis is the development of car-
diac dysfunction also described as septic cardiomyop-
athy. We have previously shown that neutralization of
IL-17A by antibody during CLP profoundly reduced the
ex vivo release of proinflammatory mediators such IL-6,
MIP-2 (CXCL1) and MIP-1α (CCL3) from murine cardi-
omyocytes [28]. Further studies will be needed to define
the mechanisms by which IL-17 s and IL-23 interfere
with cardiac function during sepsis, especially with re-
spect to the situation in humans.
Humans with genetic polymorphisms in the genes for
IL-17 or IL-23
As for many genes with immune functions, several natur-
ally occurring mutations for the IL-17 and IL-23 systems
have been described [30–32]. More than 10 different single
nucleotide polymorphisms in the gene for IL-23 or for the
IL-23 receptor (IL-23R) have been identified [33]. For ex-
ample, the IL-23R Arg381Gln mutation is associated with
development of autoimmune disease [32]. Mutations in
genes of the IL-17 system result in a defective immune
responses to bacterial and fungal pathogens in certain clin-
ical situations. Specifically, humans with the autosomal
dominant hyper-IgE syndrome have a disability in the dif-
ferentiation of Th17 cells accompanied with an impaired
production of IL-17 [31]. Such individuals suffer from re-
current pulmonary infections, staphylococcal abscesses
and mucocutaneous candidiasis. In other forms of chronic
mucocutaneous candidiasis disease, presenting with recur-
rent or persistent infections with Candida albicans, asso-
ciations with either an autosomal recessive deficiency in
the IL-17 receptor A (IL-17RA) or autosomal dominant
deficiency in IL-17 F have been described [30]. To date it
is not known, if any of such disruptions in the genes of
the IL-17/IL-23 axis are influencing the risk for the devel-
opment of sepsis, probability of surviving sepsis or altera-
tions in the immune surveillance after recovery from
sepsis.Review
The IL-23 and IL-17 families of cytokines were originally
thought to play roles in innate immune responses to
contain bacterial and fungi. There is emerging evidence
that these cytokines may also play adverse roles in
asthma, endotoxemia and sepsis by causing exaggerated
inflammatory responses. Obviously, much greater details
will be required if the IL-17 family and IL-23 become
potential targets for in vivo neutralization.
Conclusions
Many basic science and clinical reports have provided an
understanding of the implications of the IL-17/IL-23 axis
during autoimmune diseases. There is also emerging evi-
dence that this family of functionally related cytokines
may play a distinct role during sepsis. The current know-
ledge justifies further investigations to evaluate the role
of IL-17 family members and IL-23 during sepsis. Mono-
clonal antibodies to target IL-23 (e.g. ustekinumab, also
cross-reacting with IL-12) have been approved for the
treatment of autoimmune disease such as psoriasis [34].
Likewise, human monoclonal anti-IL-17 antibodies (e.g.
secukinumab) are under development for testing in clin-
ical trials. It remains to be seen, if such new therapeutic
agents may also have a potential benefit for patients with
severe sepsis.
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